Endocrine Society statement: variable response to GLP-1 drugs remains unexplained

The Endocrine Society issued a scientific statement acknowledging that GLP-1 receptor agonists like Ozempic and Wegovy produce variable weight-loss responses among patients, and that the mechanisms behind this variability are not fully understood. The statement highlights gaps in knowledge regarding predictors of response and long-term outcomes. This matters because it underscores the need for personalized approaches in obesity treatment and sets the research agenda.